People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other, Other Health Care, Other Technology, Pharmaceuticals, Biotechnology, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gaikai Inc. | — | Other | Series B | $43.3M | $498.4M | 2009 |
| Urotronic, Inc. | — | Other Health Care | Series B | $38.5M | $253.7M | 2018 |
| GoVyrl, Inc. | — | Other Technology | Series B | $31.5M | $45.2M | 2019 |
| Anacor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $19.4M | $83.6M | 2010 |
| Farewell LLC | — | Other Health Care | Series A | $10.8M | $85.8M | 2015 |
| Better Therapeutics, Inc. | — | Biotechnology | Series A | $8.9M | $1.7M | 2023 |
| Centercode, Inc. | — | Other Technology | Seed | $7.5M | $136.3M | 2019 |
| Hydraulex International Holdings, Inc. | — | Manufacturing | Series A | $7.5M | $74.9M | 2016 |
| High Rise Beverage Company, LLC | — | Food & Beverage | Pre-Seed | $2.1M | $2.4M | 2024 |
| Optilume Stricture, LLC | — | Other Health Care | Pre-Seed | $954K | $25.8M | 2020 |
| Amnis Corp | — | Biotechnology | Pre-Seed | $894K | $49.3M | 2009 |
David Perry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Perry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nate Redmond | 2 | 15 |
| Hui Hu | 2 | 4 |
| Lixiao Wang | 2 | 4 |
| Jeff Thomas | 2 | 4 |
| Doug Kohrs | 2 | 3 |
| Yuriy Prilutskiy | 2 | 3 |
| Geoffrey Parker | 2 | 3 |
| Tan Ching | 2 | 2 |
| Carl Gordon | 1 | 24 |
| Annette Campbell-White | 1 | 11 |
| Mitch Lasky | 1 | 9 |
| Mark Leschly | 1 | 9 |
| Paul Voois | 1 | 7 |
| Jason Goldberg | 1 | 7 |
| Paul Klingenstein | 1 | 6 |
| Richard Campbell | 1 | 5 |
| William G. Connors | 1 | 5 |
| Anders Hove | 1 | 4 |
| JAMES HALE | 1 | 4 |
| William Rieflin | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.